Global Drive for Primary Health Care Gains Ground at World Health Assembly: A Unified Call to Action In a powerful demonstration of international unity and purpose, global health leaders convened at a pivotal side event during the Seventy-eighth World Health…
Legend Biotech Unveils Landmark Five-Year Survival Data for CARVYKTI® in Relapsed/Refractory Multiple Myeloma at ASCO 2025 Legend Biotech Corporation,a global leader in cell therapy innovation, presented groundbreaking long-term data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting,…
Takeda Secures European Commission Approval for ADCETRIS® in Combination with ECADD as a New Frontline Therapy for Adults with Advanced-Stage Hodgkin Lymphoma Takeda has announced a major milestone in the treatment landscape for Hodgkin lymphoma with the European Commission’s (EC)…
ASCO 2025: Subcutaneous Sarclisa with On-Body Injector Shows Promise in Multiple Myeloma Treatment At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Sanofi presented promising data from two pivotal clinical trials evaluating the investigational subcutaneous (SC) delivery of…
AbbVie Launches Second Annual Migraine Career Catalyst Award to Empower People with Migraine in Pursuit of Their Professional Dreams Pharmaceutical company AbbVie has announced the return of its AbbVie Migraine Career Catalyst Award™, a unique initiative designed to support individuals…
Roche Announces Positive Phase III IMforte Study Results: Tecentriq Combined with Lurbinectedin Demonstrates Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer Roche today reported promising outcomes from the pivotal Phase III IMforte clinical trial evaluating the combination of Tecentriq®…
Biotech Industry Sounds Alarm on Trump Tariffs, Citing Threats to Rare Disease and Advanced Therapies Despite billions of dollars being funneled into reshoring pharmaceutical manufacturing to U.S. soil, the biotech industry is sounding the alarm over looming tariffs proposed by…
BioNTech and Bristol Myers Squibb Forge $11.1 Billion Global Partnership to Advance Bispecific Cancer Antibody BNT327 Across Multiple Solid Tumor Types In a move that signals a major step forward in the fight against some of the most challenging forms…
Genmab Unveils Promising Phase 1/2 Data for Rina-S® in Heavily Pretreated Advanced Endometrial Cancer at ASCO 2025 Genmab A/S, a leading biotechnology company specializing in antibody-based therapies for cancer, has announced new clinical data from the Phase 1/2 RAINFOL™-01 trial…
BeOne Medicines Showcases Early Clinical Success of Two Innovative Breast Cancer Therapies at ASCO 2025 BeOne Medicines Ltd. a global biotechnology company dedicated to developing targeted therapies for cancer, announced promising new data from two early-stage breast cancer drug candidates…
Viatris Reports Positive Phase 3 Results for MR-142, Advancing a Potential First-in-Class Treatment for Night Vision Impairment in Keratorefractive Patients Viatris Inc. a global healthcare company committed to bridging access and innovation, announced today that its investigational drug candidate MR-142…
Jazz Pharmaceuticals Reports Landmark Phase 3 Results for Zepzelca and Tecentriq Combo as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc has announced highly promising results from its global Phase 3 IMforte clinical trial, which evaluated…